MiMedx Group (NASDAQ:MDXG) Stock Price Down 8.8% – What’s Next?

MiMedx Group, Inc (NASDAQ:MDXG)’s share price dropped 8.8% during trading on Thursday . The stock traded as low as $4.96 and last traded at $4.8160. Approximately 508,892 shares traded hands during trading, a decline of 46% from the average daily volume of 945,096 shares. The stock had previously closed at $5.28.

More MiMedx Group News

Here are the key news stories impacting MiMedx Group this week:

• Positive Sentiment: Q4 2025 results beat expectations — MiMedx reported $0.14 EPS vs. a $0.09 consensus and revenue of $118.1M vs. ~$106.8M expected, with improved margins and 27% ROE, supporting profitability progress. Q4 beat article
• Positive Sentiment: Company reported record Q4 and full‑year operating results and adjusted EBITDA of $29M (25% of net sales); management also authorized a $100M share repurchase program — a tangible capital-return action that can support the stock. Press release
• Neutral Sentiment: Management hosted an earnings call and published transcripts providing more color on surgical growth initiatives and reimbursement headwinds; these details will matter for modeling conversion of demand and margin sustainability. Earnings call transcript
• Neutral Sentiment: Analyst attention increased with coverage initiation from Citizens/JMP, which can boost liquidity and investor focus but not immediately change fundamentals. Coverage article
• Neutral Sentiment: Expanded public record of the call and earnings (transcripts and Yahoo/MarketBeat recaps) gives investors more primary material to re‑assess guidance assumptions. Call transcript
• Negative Sentiment: 2026 revenue guidance of $340M–$360M was below the consensus (~$375M), raising concerns that growth could decelerate due to reimbursement changes and slower near‑term adoption; that guidance miss likely drove the stock downward. Guidance article

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MDXG. Mizuho reduced their price target on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, December 17th. Cantor Fitzgerald decreased their target price on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 17th. Citigroup initiated coverage on shares of MiMedx Group in a research note on Monday. They set a “market outperform” rating on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Finally, Lake Street Capital cut their price objective on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.60.

MiMedx Group Price Performance

The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95. The company’s 50 day simple moving average is $5.78 and its 200 day simple moving average is $6.60. The company has a market capitalization of $732.35 million, a PE ratio of 18.28 and a beta of 1.59.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%.The business had revenue of $118.10 million during the quarter, compared to the consensus estimate of $106.78 million. As a group, sell-side analysts predict that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

Institutional Investors Weigh In On MiMedx Group

A number of hedge funds and other institutional investors have recently bought and sold shares of MDXG. Divisadero Street Capital Management LP grew its stake in MiMedx Group by 362.9% in the 2nd quarter. Divisadero Street Capital Management LP now owns 223,220 shares of the company’s stock valued at $1,364,000 after acquiring an additional 175,000 shares during the last quarter. Hussman Strategic Advisors Inc. purchased a new position in MiMedx Group in the third quarter valued at about $1,759,000. Trigran Investments Inc. lifted its position in shares of MiMedx Group by 10.4% during the second quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock worth $51,266,000 after purchasing an additional 790,901 shares in the last quarter. SG Americas Securities LLC grew its stake in MiMedx Group by 419.3% during the 3rd quarter. SG Americas Securities LLC now owns 161,960 shares of the company’s stock valued at $1,130,000 after purchasing an additional 130,769 shares in the last quarter. Finally, Integrated Quantitative Investments LLC bought a new stake in shares of MiMedx Group in the 2nd quarter worth about $305,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.